Non-Small-Cell Lung Cancer – Geographic Focus: China – Non-Small-Cell Lung Cancer – China In-Depth (China) – 2021

Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related death in China—has a highly dynamic drug development pipeline, including several targeted and biomarker-driven therapies. Notably, many targeted therapies are intended for patients with activating EGFR mutations, which are more prevalent in China than in the Western markets. We expect China’s NSCLC therapy market to experience robust growth throughout the 2020-2030 forecast period. The key driver of this market growth will be the continued uptake of targeted and biomarker-driven therapies, including immune checkpoint inhibitors, EGFR inhibitors, and ALK inhibitors, following the incorporation of several therapies into China’s National Reimbursement Drug List (NRDL), thereby securing better patient access. Moreover, newer targeted therapies are expected to be approved within the forecast period, which will result in increased therapy options and market growth.


  • How large is China’s drug-treatable NSCLC population, and how will drug-treatment rates change during the forecast period?
  • Which are the most commercially relevant drugs in China’s NSCLC market and why? What are interviewed experts’ insights into current treatment options?
  • What are the key market access considerations for therapies in the NSCLC pipeline in China? What sales/uptake could these agents secure in NSCLC? What are interviewed experts’ opinions of key emerging therapies?
  • What are the key drivers and constraints in the China NSCLC therapy market, and how will the market evolve over the forecast period?


China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.

Release date

March 2021



Primary Research

Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with hematologist-oncologists. Supported by survey data collected for this and other DRG research.


Diagnosed incidence of NSCLC in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations.


10-year, annualized, drug-level sales and patient share of key NSCLC therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions.


Phase III/PR: > 20 drugs. Phase II: 20+ drugs. Coverage of select early-phase products.

Table of contents

  • Non-Small-Cell Lung Cancer - Geographic Focus: China - Non-Small-Cell Lung Cancer - China In-Depth (China) - 2021
    • Non-Small-Cell Lung Cancer - China In-Depth (China)

launch Related Market Assessment Reports